C3:CH50 ratio as a proposed composite marker for eculizumab monitoring in atypical hemolytic uremic syndrome: Preliminary results.
about
C3:CH50 ratio as a proposed composite marker for eculizumab monitoring in atypical hemolytic uremic syndrome: Preliminary results.
description
2016 nî lūn-bûn
@nan
2016 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
C3:CH50 ratio as a proposed co ...... syndrome: Preliminary results.
@ast
C3:CH50 ratio as a proposed co ...... syndrome: Preliminary results.
@en
type
label
C3:CH50 ratio as a proposed co ...... syndrome: Preliminary results.
@ast
C3:CH50 ratio as a proposed co ...... syndrome: Preliminary results.
@en
prefLabel
C3:CH50 ratio as a proposed co ...... syndrome: Preliminary results.
@ast
C3:CH50 ratio as a proposed co ...... syndrome: Preliminary results.
@en
P2093
P2860
P1476
C3:CH50 ratio as a proposed co ...... syndrome: Preliminary results.
@en
P2093
Djamila Batouche
Fatma Haiba
Kheir Eddine Kerboua
P2860
P304
P356
10.1080/15321819.2016.1234485
P577
2016-09-12T00:00:00Z